MEVION S250-FIT Proton Therapy System Gains CE Mark Approval

Mevion Medical Systems has received CE Mark approval for the MEVION S250-FIT Proton Therapy System, less than a year after the product earned U.S. Food and Drug Administration 510(k) clearance.

The MEVION S250-FIT is reportedly the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption, according to the company. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients.

“With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is positioned to transform how proton therapy is delivered worldwide,” Mevion Medical Systems President/CEO Tina Yu, Ph.D., said. “For European health systems that have long recognized the clinical benefits of proton therapy but faced significant infrastructure and financial barriers, the S250-FIT offers a fundamentally new approach, one that brings high-quality proton therapy directly into existing treatment environments. This is a defining moment for accessible cancer care in Europe and beyond.”

The MEVION S250-FIT system features Mevion’s HYPERSCAN pencil beam scanning platform for Intensity Modulated Proton Therapy (IMPT), delivering highly conformal dose distributions with hyper-fast energy layer switching and the Adaptive Aperture proton multi-leaf collimator (pMLC).

The MEVION S250-FIT platform is built to support DirectARC proton arc therapy, enabling VMAT-like speed and efficiency in proton treatment delivery.

The system incorporates a large-bore diagnostic computed tomography aligned to the isocenter, enabling advanced image-guided radiation therapy (IGRT) and adaptive treatment workflows. An upright patient positioning system from Leo Cancer Care enhances flexibility in patient setup and enables treatment positions that may offer clinical advantages for select tumor sites. The platform is also FLASH research ready.*

The CE Mark follows the growing adoption of the MEVION S250-FIT platform. Mevion has signed contracts with nine leading institutions globally and announced installations and partnerships with major medical centers, including Stanford Health Care, BayCare Health System, Atlantic Health System, University of Nebraska Medical Center, Loma Linda University Health, and UNC Health.

The MEVION S250-FIT architecture also builds on the foundation of the MEVION S250i platform, which has been operational at ZON-PTC at Maastro Clinic in the Netherlands, since 2018.

Mevion Medical Systems provides compact proton therapy systems for cancer care. Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy. Since 2013, Mevion compact proton therapy single-room systems have been used by cancer centers for treating patients. Mevion’s products, including the flagship MEVION S250i and MEVION S250-FIT with HYPERSCAN pencil beam scanning, represent the world’s most compact proton therapy systems that eliminate the obstacles of size, complexity, and cost. Mevion is headquartered in Littleton, Mass., with a presence in Europe and Asia.

* For research use only and requires additional evaluation prior to use.